322 related articles for article (PubMed ID: 23728349)
1. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
2. Disruption of β-catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair.
Moheimani F; Roth HM; Cross J; Reid AT; Shaheen F; Warner SM; Hirota JA; Kicic A; Hallstrand TS; Kahn M; Stick SM; Hansbro PM; Hackett TL; Knight DA
Int J Biochem Cell Biol; 2015 Nov; 68():59-69. PubMed ID: 26315281
[TBL] [Abstract][Full Text] [Related]
3. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.
Kim YM; Ma H; Oehler VG; Gang EJ; Nguyen C; Masiello D; Liu H; Zhao Y; Radich J; Kahn M
Curr Cancer Drug Targets; 2011 Feb; 11(2):213-25. PubMed ID: 21158719
[TBL] [Abstract][Full Text] [Related]
4. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
Kartha VK; Alamoud KA; Sadykov K; Nguyen BC; Laroche F; Feng H; Lee J; Pai SI; Varelas X; Egloff AM; Snyder-Cappione JE; Belkina AC; Bais MV; Monti S; Kukuruzinska MA
Genome Med; 2018 Jul; 10(1):54. PubMed ID: 30029671
[TBL] [Abstract][Full Text] [Related]
5. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
Zhao Y; Masiello D; McMillian M; Nguyen C; Wu Y; Melendez E; Smbatyan G; Kida A; He Y; Teo JL; Kahn M
Oncogene; 2016 Jul; 35(28):3705-17. PubMed ID: 26657156
[TBL] [Abstract][Full Text] [Related]
6. Sam68 Allows Selective Targeting of Human Cancer Stem Cells.
Benoit YD; Mitchell RR; Risueño RM; Orlando L; Tanasijevic B; Boyd AL; Aslostovar L; Salci KR; Shapovalova Z; Russell J; Eguchi M; Golubeva D; Graham M; Xenocostas A; Trus MR; Foley R; Leber B; Collins TJ; Bhatia M
Cell Chem Biol; 2017 Jul; 24(7):833-844.e9. PubMed ID: 28648376
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Human Airway Epithelial Tissue Stem Cell Differentiation by β-Catenin, P300, and CBP.
Malleske DT; Hayes D; Lallier SW; Hill CL; Reynolds SD
Stem Cells; 2018 Dec; 36(12):1905-1916. PubMed ID: 30171668
[TBL] [Abstract][Full Text] [Related]
8. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression.
Ma H; Nguyen C; Lee KS; Kahn M
Oncogene; 2005 May; 24(22):3619-31. PubMed ID: 15782138
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
[TBL] [Abstract][Full Text] [Related]
10. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Wend P; Fang L; Zhu Q; Schipper JH; Loddenkemper C; Kosel F; Brinkmann V; Eckert K; Hindersin S; Holland JD; Lehr S; Kahn M; Ziebold U; Birchmeier W
EMBO J; 2013 Jul; 32(14):1977-89. PubMed ID: 23736260
[TBL] [Abstract][Full Text] [Related]
11. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
[TBL] [Abstract][Full Text] [Related]
13. Interactions between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP).
Zhou B; Liu Y; Kahn M; Ann DK; Han A; Wang H; Nguyen C; Flodby P; Zhong Q; Krishnaveni MS; Liebler JM; Minoo P; Crandall ED; Borok Z
J Biol Chem; 2012 Mar; 287(10):7026-38. PubMed ID: 22241478
[TBL] [Abstract][Full Text] [Related]
14. Safely targeting cancer stem cells via selective catenin coactivator antagonism.
Lenz HJ; Kahn M
Cancer Sci; 2014 Sep; 105(9):1087-92. PubMed ID: 24975284
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
16. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
17. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
18. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population.
Liu Y; Chen H; Zheng P; Zheng Y; Luo Q; Xie G; Ma Y; Shen L
J Exp Clin Cancer Res; 2017 Sep; 36(1):125. PubMed ID: 28893318
[TBL] [Abstract][Full Text] [Related]
19. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.
Arensman MD; Telesca D; Lay AR; Kershaw KM; Wu N; Donahue TR; Dawson DW
Mol Cancer Ther; 2014 Oct; 13(10):2303-14. PubMed ID: 25082960
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
